PhotoPoint MV6401

PhotoPoint MV6401

An experimental agent which effects primary closure of the choriocapillaris and moderately sized choroidal vessels in rats, and may be of use as a photodynamic therapy if it has the same effect in humans.
References in periodicals archive ?
During 2003, Miravant continued its preclinical research studies of PhotoPoint MV6401 to treat solid tumor cells and the new blood vessels that support tumor growth.
Miravant Announces Fourth Quarter and 2003 Results
Included are topical drug PhotoPoint MV9411, now in phase II clinical trials for treating plaque psoriasis, and PhotoPoint MV6401, Miravant's preclinical oncology drug recently published in two cover articles of the preeminent journal "Cancer Research.
Miravant Receives U.S. Patent for Highly Potent Classes of Light Activated Drugs; Patent Covers Dermatology Drug MV9411 Now in Phase II Clinical Trials for Psoriasis
In an advanced orthotopic breast tumor model (breast cancer grown in mammary tissue), PhotoPoint MV6401 caused selective destruction of tumor cells and the new blood vessels that sustain their growth, achieving tumor eradication or long-term tumor growth delay.
Miravant Announces Second Quarter Results
At the Steele Laboratory, Miravant's PhotoPoint MV6401 drug was studied as a combined anti-vascular and cellular targeting agent in an advanced orthotopic model (breast cancer grown in mammary tissue).
In this study of PhotoPoint MV6401, we were able to use a fractionated drug dose to simultaneously target the breast cancer tumor cells and at the same time destroy the blood vessels that support these cancer cells.
PhotoPoint PDT Targets Both Tumor Cells and Blood Vessels in Preclinical Breast Cancer Study; Results Published in August 1st Issue of Journal ``Cancer Research''
Data to be presented at AACR demonstrate that PhotoPoint MV6401 selectively localizes to the neovasculature of orthotopic mammary tumors.
Miravant's PhotoPoint PDT Arrests Tumor Growth by Destroying Tumor Blood Vessels
Medical browser ?
Full browser ?